The paper uses ketamine as a case study to show that market and regulatory failures allowed a costly patented intranasal s‑ketamine (Spravato®) to be commercialised while inexpensive generic racemic ketamine—apparently at least as effective—remained under‑evaluated and largely inaccessible. The authors recommend systemic reforms, including commercial incentives, public and public–private funding, reduced regulatory barriers and coordinated international funding, to ensure affordable off‑patent treatments become accessible.
- Published
- Journal
- Australian and new-zealand Journal of Psychiatry
- Authors
- Rodgers, A., Bahceci, D., Davey, C. G., Chatterton, M. L., Glozier, N., Hopwood, M., Loo, C.